A Historical Cannabis Review Distinguished Tolerance to Side Effects From Tolerance to Treatment Targets

A 1981 review emphasized that tolerance can have different clinical implications depending on which effect becomes weaker. Reduced adverse effects and reduced response on a treatment target should not be described as the same therapeutic development.

Tolerance needs an identified endpoint

The source discussed cardiovascular, autonomic, sleep and behavioral adaptation, with dose and administration schedule affecting its acquisition. A general statement that someone is tolerant leaves unanswered which response changed and under what exposure history.

Adaptation can have different practical meanings

A reduction in an unwanted effect may improve tolerability, while a reduction in a desired effect may undermine the original treatment goal. The distinction is conceptual; the review does not establish a modern dosing strategy for epilepsy, pain or any other condition it discussed.

Dependence is a separate inference

The review described withdrawal observations and distinguished their clinical significance from drug-seeking behavior, which has multiple determinants. Withdrawal, tolerance and a use-disorder diagnosis should not be substituted for one another. Its historical characterization of withdrawal severity should not be treated as a universal current estimate.

Interpreting the evidence

For a clinical tolerance claim, specify whether the endpoint is an adverse reaction, desired benefit or another response. This review supplies an interpretive distinction rather than evidence that adaptation necessarily improves treatment or that a tolerant person is free of functional effects.

Related reading: interpreting cannabis tolerance claims.

Research reference

Jones RT; Benowitz NL; Herning RI (1981). Clinical relevance of cannabis tolerance and dependence. Journal of clinical pharmacology. doi:10.1002/j.1552-4604.1981.tb02589.x.

This analysis draws on the supplied abstract of a historical review.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us